Instant Clot-Forming and Antibacterial Dressings: Innovations with Tranexamic Acid

Study Background and Research Question

Traumatic injuries, ranging from accidents to combat wounds, remain a leading cause of mortality globally, with uncontrolled hemorrhage and subsequent infection accounting for a significant proportion of early deaths. According to the reference study, excessive blood loss is implicated in nearly 30% of trauma-related fatalities, while infection risk escalates within 72 hours post-injury. This dual threat underscores the need for wound dressings that can both induce rapid hemostasis and actively prevent infection. Among hemostatic strategies, antifibrinolytic agents such as Tranexamic Acid have shown efficacy in stabilizing clots and reducing bleeding time, but their integration with antimicrobial modalities in a single wound dressing has remained a technical challenge.

Key Innovation from the Reference Study

The study introduces a bi-layer wound dressing system that leverages a synergistic combination of Tranexamic Acid (TXA), S-nitroso-N-acetylpenicillamine (SNAP, an NO donor), and propolis. The innovation lies in the spatial configuration: the wound-facing layer is composed of TXA embedded in a resinous propolis bed, while the backing layer contains SNAP within a Carbosil® (polycarbonate urethane-silicone) polymer matrix. The TXA–SNAP–propolis (T-SP) design enables immediate clot formation by inhibiting fibrinolysis at the wound interface and delivers sustained antimicrobial nitric oxide release—together addressing the two most critical complications of trauma wounds.

Methods and Experimental Design Insights

The fabrication of the T-SP dressing employed a strategic, bi-layer approach. The wound-contacting layer consisted of TXA suspended in propolis at varying concentrations (2.5%, 5.0%, and 7.5% by volume). Propolis, chosen for its natural bioadhesive and antibacterial properties, provided a stable matrix for TXA deployment. The base layer, distant from the wound, housed the NO donor SNAP embedded in a Carbosil® copolymer, permitting controlled NO release.

Key experimental procedures included:

• A lactate dehydrogenase-based platelet adhesion assay to assess clot initiation and stability.
• Scanning electron microscopy (SEM) to visualize fibrin network formation and clot density.
• Antibacterial efficacy testing against Staphylococcus aureus and multidrug-resistant Acinetobacter baumannii using colony-forming unit (CFU) reduction measurements.

This multi-pronged evaluation allowed the researchers to quantify both the hemostatic and antimicrobial performance of the dressings.

Core Findings and Why They Matter

The primary outcomes of the study are summarized as follows:

• Rapid Clot Formation: The T-SP dressing with 7.5% propolis and TXA induced a marked increase in fibrin activation and clot density within 15 minutes of application, as evidenced by the platelet adhesion assay and SEM imaging.
• Stabilization of Clot Structure: Dense fibrin networks were formed, attributed to TXA's inhibition of fibrinolysis. TXA acts as a competitive inhibitor of plasminogen activation, thus preventing premature clot breakdown at the wound site.
• Potent Antibacterial Activity: The NO-releasing and propolis components achieved a 98.9% reduction in S. aureus and a 99.4% reduction in multidrug-resistant A. baumannii CFU counts, highlighting the dual-action nature of the T-SP design.

Taken together, these findings indicate that the bi-layer dressing offers an effective solution for simultaneous bleeding time reduction and infection control in trauma injuries. The rapid stabilization of clots through inhibition of fibrinolysis is particularly relevant for situations where immediate hemostasis is critical, such as battlefield or remote trauma care.

Protocol Parameters

• Tranexamic Acid concentration: 7.5% (w/v) in propolis for optimal clot initiation in the wound-contacting layer.
• NO donor (SNAP) loading: Embedded within Carbosil®; release kinetics tailored for sustained antimicrobial activity (release rates detailed in the original paper).
• Platelet adhesion assay timing: 15 minutes post-application to assess early fibrin network formation.
• SEM evaluation: Post-clot formation to confirm fibrin density and structural integrity.
• Antibacterial efficacy testing: Performed using standard CFU reduction protocols against clinically relevant bacterial strains.

Comparison with Existing Internal Articles

The present study's bi-layer T-SP design builds directly upon advances in antifibrinolytic research outlined in several recent internal reviews:

• The article "Instant Clot-Forming Wound Dressings with Tranexamic Acid and NO" previously described early-stage concepts for combining antifibrinolytic and NO-based antimicrobial mechanisms, but the current reference paper provides more comprehensive experimental validation, especially regarding the synergistic effect of propolis.
• Mechanistic insights into Tranexamic Acid's role as an antifibrinolytic agent are extensively discussed in "Tranexamic Acid: Mechanistic Leverage for Translational Hemostasis", which contextualizes TXA's competitive inhibition of plasminogen activation in both in vitro and translational trauma models. The bi-layer dressing's performance in rapidly stabilizing clots aligns well with these mechanistic underpinnings.
• For researchers seeking practical assay workflows, "Tranexamic Acid in Fibrinolysis Research: Applied Protocols & Innovations" outlines protocol optimization for plasmin-induced neutrophil adherence assays and bleeding time reduction models, which are relevant for adapting the T-SP dressing to diverse experimental frameworks.

Collectively, the current study contributes a validated, integrative platform that links antifibrinolytic and antimicrobial strategies for acute wound care.

Limitations and Transferability

While the study demonstrates robust in vitro and ex vivo performance, several limitations should be acknowledged. The dressing's efficacy was established in controlled laboratory settings; further in vivo validation in animal or clinical trauma models is necessary to confirm long-term biocompatibility and real-world effectiveness. The concentration-dependent effects of propolis and TXA also suggest that optimization may be required for specific wound types or patient populations. Additionally, the transferability to large-scale manufacturing and regulatory approval for clinical use remains to be addressed.

Research Support Resources

Researchers aiming to replicate or extend these findings in fibrinolysis research or trauma wound models can leverage high-purity reagents for consistent assay performance. Tranexamic Acid (SKU B1858) from APExBIO offers quality-controlled material suitable for both in vitro and in vivo workflows, supporting studies on clot stability, inhibition of fibrinolysis, and bleeding time reduction. For detailed guidance on integrating antifibrinolytic agents in translational protocols, consult recent internal reviews on assay optimization and mechanistic workflows.